Abstract
Objective
There is considerable variability in the individual pharmaceutical dosages required to achieve optimal therapeutic effects, which may be due to environmental or genetic factors. The objective of this study was to test the presence of the CYP2C9*3 allelic variant in the Chinese population and to investigate the association of this variant with both metabolism and therapeutic efficacy of irbesartan on essential hypertension.
Methods
In this study, we enrolled 711 subjects from Taihu County and 376 subjects from Dongzhi County in Anhui Province, China. All subjects received a single oral dose of 150 mg irbesartan daily for 28 days. The plasma concentration of irbesartan at 24 h after dosing on the 27th day and at 6 h after dosing on the 28th day was detected using fluorescence-high-performance liquid chromatography. CYP2C9 genotypes were determined using polymerase chain reaction—restriction fragment length polymorphism.
Results
No CYP2C9*2 allele was found in 235 Chinese samples and was removed from further study. The mean frequency of the CYP2C9*3 allele was 3.65%, while no CYP2C9*3/*3 genotype was detected. Multiple linear regression analyses revealed that the CYP2C9*3 allele carriers had significantly higher irbesartan concentrations in plasma at 6 h (Taihu: P<0.0001; Dongzhi: P=0.03) and 24 h (Taihu: P<0.0001; Dongzhi: P=0.00013) after dosing. No significant association was found between the CYP2C9*3 allelic variant and the therapeutic effect of irbesartan on essential hypertension.
Conclusion
Our study suggests that the CYP2C9*3 plays an important role in the metabolism of irbesartan and/or is in linkage disequilibrium with another potential CYP2C9 allele, both of which possibly modify the pharmacokinetics of irbesartan.
Similar content being viewed by others
References
Babaoglu MO, Yasar U, Sandberg M, Eliasson E, Dahl ML, Kayaalp SO, Bozkurt A (2004) CYP2C9 genetic variants and losartan oxidation in a Turkish population. Eur J Clin Pharmacol 60(5):337–342
Bhasker CR, Miners JO, Coulter S, Birkett DJ (1997) Allelic and functional variability of cytochrome P4502C9. Pharmacogenetics 7:51–58
Bourrié M, Meunier V, Berger Y, Fabre G (1999) Role of Cytochrome P-450 2C9 in irbesartan oxidation by human liver microsomes. Drug Metab and Dispos 27(2):288–296
Cazaubon C, Gougat J, Bousquet F, Guiraudou P, Gayraud R, Lacour C, Roccon A, Galindo G, Barthelemy G, Gautret B (1993) Pharmacological characterization of SR 47436, a new nonpeptide AT1 subtype angiotensin II receptor antagonist. J Pharmacol Exp Ther 265:826–834
Chando TJ, Everett DW, Kahle AD et al (1998) Biotransformation of irbesartan in man. Drug Metab Dispos 26(5):408–417
Crespi CL, Miller VP (1997) The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH: Cytochrome P450 oxidoreductase. Pharmacogenetics 7:203–210
Dickmann LJ, Rettie AE, Kneller MB, Kim RB, Wood AJ, Stein CM, Wilkinson GR, Schwarz UI (2001) Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African-Americans. Mol Pharmacol 60:382–387
Fierens FLP, Vanderheyden PML, De Backer J-P, Vauquelin G (1999) Insurmountable angiotensin AT1 receptor antagonist: the role of tight antagonist binding. Eur J Pharmacol 372:199–206
Hallberg P, Karlsson J, Kurland L, Lind L, Kahan T, Malmqvist K, Ohman KP, Nystrom F, Melhus H (2002) The CYP2C9 genotype predicts the blood pressure response to irbesartan: result from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs. Atenolol(SILVHIA) trial. J Hypertens 20(10):2089–2093
Hans R, Brunner (1997) The new angiotensin II receptor antagonist, irbesartan. pharmacokinetic and pharmacodynamic considerations. Am J Hypertens 10:311S–317S
Ho PC, Abbott FS, Zanger UM, Chang TK (2003) Influence of CYP2C9 genotypes on the formation of a hepatotoxic metabolite of valproic acid in human liver microsomes. Pharmacogenomics J 3(6):335–342
Klose TS, Blaisdell JA, Goldstein JA (1999) Gene structure of CYP2C8 and extrahepatic distribution of the hyman CYP2Cs. J Biochem Mol Toxicol 13:289–295
Lee CR, Goldstein JA, Pieper JA(2003) Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics 12:251–263
Miners JO, Birkett DJ (1998) Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 45:525–538
Perrier L, Bourrie M, Marti E (1994) In vitro N-glucuronidation of SR 47436(BMS 186295), a new AT1 nonpeptide angiotensin II receptor antagonist, by rat, monkey and human hepatic microsomal fractions. J Pharmacol Exp Ther 271:91–99
Reeves RA, Lin CS, Kassler-Taub K, Pouleur H (1998) Dose-related efficacy of irbesartan for hypertension. Integrated Anal Hypertens 31(6):1311–1316
Scordo MG, Pengo V, Spina E (2002) Influence of CYP2C9 and CYP2C19 genetic polymorphism on warfarin maintenance dose and metabolic clearance. Clin Pharmacol Ther 72:702–710
Sim SC, Ingelman-Sunberg M, Daly AK et al (2005) Human cytochrome P450 (CYP) allele nomenclature committee (website); http://www.imm.ki.se/CYPalleles/
Sullivan-Klose TH, Ghanayem BI, Bell DA et al (1996) J.A. The role for the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 6:341–349
Takahashi H, Echizen H (2001) Pharmacogenetics of warfarin elimination and its clinical implications. Clin Pharmacokinet 40:587–603
Takanashi K, Tainaka H, Kobayashi K, Yasumori T, Hosakawa M, Chiba K (2000) CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates. Pharmacogenetics 10:95–104
Takahashi H, Wilkinson GR, Caraco Y et al (2003) Population differences in (S)-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese. Clin Pharmacol Ther 73:253–263
Timmermans PBMWM, Smith RD (1994) Angiotensin II receptor subtypes: selective antagonists and functional correlates. Eur Heart J 15(Suppl D):79–87
Vachharajani NN, Shyu WC, Chando TJ, Everett DW, Greene DS, Barbhaiya RH (1998) Oral bioavailability and disposition characteristics of irbesartan, an angiotensin antagonist, in healthy volunteers. J Clin Pharmacol 38(8):702–707
Vachharajani NN, Shyu WC, Smith RA, Greene DS (1998) The effects of age and gender on the pharmacokinetics of irbesartan. Br J Clin Pharmacol 46(6):611–613
Wen SY, Wang H, Sun OJ, Wang SQ (2003) Rapid detection of the known SNPs of CYP2C9 using oligonucleotide microarray. World J Gastroenterol 9(6):1342–1346
Yoon YR, Shon JH, Kim MK, Lim YC, Lee HR, Park JY, Cha IJ, Shin JG (2001). Frequency of cytochrome P450 2C9 mutant alleles in a Korean population. Br J Clin Pharmacol 51:277–280
Yu BN, Luo CH, Wang D, Wang A, Li Z, Zhang W, Mo W, Zhou HH (2004) CYP2C9 allele variants in Chinese hypertension patients and healthy controls. Clin Chim Acta 348(1–2):57–61
Zhang S, Liu P, Jiang S, Hong X, **ng H, Xu X (2005) Association of cigarette smoking with steady-state plasma concentration of irbesartan in male Chinese with hypertension. Methods Find Exp Clin Pharmacol 27(3):173–178
Zhao F, Loke C, Rankin SC et al (2004) Novel CYP2C9 genetic variants in Asian subjects and their influence on Maintenance warfarin dose. Clin Pharmacol Thr 76(3):210–219
Acknowledgements
This study was supported in part by Anhui Provincial Ministry of Education, Anhui Medical University Biomedical Institute. We would like to thank the faculty and staff of the Anhui Medical University and of the Program of Population Genetics at Harvard School of Public Health. We are also grateful to all study participants and their families for their assistance and cooperation. We would like to thank Dr. Scott Venners and Dr. ** Xu
Corresponding author
Rights and permissions
About this article
Cite this article
Hong, X., Zhang, S., Mao, G. et al. CYP2C9*3 allelic variant is associated with metabolism of irbesartan in Chinese population. Eur J Clin Pharmacol 61, 627–634 (2005). https://doi.org/10.1007/s00228-005-0976-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-005-0976-8